Weatherford Director Buys $1.6M
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:09AM 11/27/09
Founder Scott Cook Sells $14.7M Worth of Intuit
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:21AM 11/25/09
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
08:00AM 11/24/09
Poniard Finds Cash to Keep Lights On: BioBuzz
Poniard faces a cash-crunch situation after a failed drug test last week.
12:59PM 11/23/09
Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz
Shareholders are on the hook for a generous loan repayment to Cel-Sci's founder.
10:14AM 11/23/09
FDA Issues New Obesity Drug Heart Warning: BioBuzz
Safety of Abbott's Meridia may heighten concerns for all weight-loss drugs
08:15AM 11/23/09
Four Senior Executives Join Orexigen(R) Therapeutics Management Team
Seasoned Executives Bring Significant Commercial and Regulatory Experience
08:00AM 11/23/09
Vivus Shares Rise On Positive Avanafil Study Data
Vivus shares rise as erectable dysfunction drug avanafil meets late-stage study goal
11:55AM 11/18/09
Director Magnuson Sells $9.5M Worth of Digital Realty Trust
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:01AM 11/17/09
Digital River CEO Buys $5M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
11:49AM 11/13/09
Weighing In on a New Name (Stocks Under $10 $)
Despite the risky nature of the biotech sector, this company has the potential to be a Game Breaker.
01:28PM 11/10/09
Orexigen 3rd-quarter Loss Narrows On Lower Costs
Orexigen Therapeutics' 3rd-quarter loss narrows on lower costs following Contrave studies
10:05AM 11/05/09
Vivus Shares Dive Following 3rd-quarter Report
Vivus shares dive after 3rd-quarter report, but Wall Street remains focused on obesity drug
01:00PM 11/04/09
Stocks Under $10: 2 Beaten Down Buys
Portfolio Manager David Peltier discusses two stocks that look attractive, following a recent pullback.
01:09PM 11/03/09
Amylin Makes Obesity Drug Deal: BioBuzz
Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.
12:09PM 11/02/09



Connect with TheStreet